Navigation Links
Blueprint for next generation of chronic myeloid leukemia treatment
Date:8/20/2014

SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). According to the American Cancer Society, nearly 6,000 new cases of CML will be diagnosed in 2014.

Drugs already in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective at controlling the disease. They do not cure CML but control it in a way that allows patients to get back to normal life and a normal expected lifespan. Before the advent of TKIs, the five-year survival rate for CML was 30% at best; now that number is above 95%. However, 20-30% of patients with CML become resistant to one or more of the TKIs.

Most cases of CML resistance result from a single mutation in BCR-ABL, and drugs to control resistance to TKI treatment caused by various single mutations have already been discovered. But BCR-ABL compound mutants that contain two mutations in the same molecule render some or all of the available TKIs ineffective.

The research team focused on BCR-ABL compound mutants observed in patients and tested them against all approved TKIs, creating a dataset that can potentially help clinicians decide which drug will be most effective for each mutation combination. They found that none of the TKIs are effective for some compound mutations, indicating the need for further research to accommodate the growing population of CML patients. The results were published online Aug. 14 in the journal Cancer Cell.

"Fortunately, the problems we are studying affect a minority of CML patients, but still this leaves some patients with no good treatment option at all," said Thomas O'Hare, PhD, an HCI investigator and co-senior author of the study. He is also a research associate professor of Internal Medicine, Division of Hematology and Hematologic Malignancies. "Our goal is to have a TKI option for every patient."

"We were able to sequence about 100 clinical samples, which gave us a very large body of data to shed light on the number of compound mutations and how they develop," said Michael Deininger, MD, PhD, co-senior author of the study, a professor of Internal Medicine, and an HCI investigator. "One key finding was that compound mutations containing an already known mutation called T315I tend to confer complete resistance to all available TKIs."

Working with HCI computational chemist Nadeem Vellore, PhD, the research team modeled at the molecular level why the drugs do not bind to certain BCR-ABL compound mutants. "This puts us in position to evaluate new drug candidates and work toward developing new treatments," said O'Hare.

"Computational analysis was one of the most interesting parts of the study. It not only confirmed what we found but showed the reason behind it," said Matthew Zabriskie, BS, co-lead author of the study. "We've established what the next level of TKI resistance is going to entail."

According to O'Hare, it is only a matter of time until analogous compound mutations emerge in many other cancers, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML). In these diseases, scientists and clinicians are still learning how to control single mutation-based resistance. "Our findings in CML will provide a blueprint for contending with resistance in these highly aggressive diseases as well," he said.


'/>"/>
Contact: Linda Aagard
801-587-7639
University of Utah Health Sciences
Source:Eurekalert  

Related biology news :

1. Genetic blueprint of bread wheat genome unveiled
2. Conservationists to create blueprint for saving Malaysias elephants
3. Salk scientists redraw the blueprint of the bodys biological clock
4. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
5. Adipose-derived stem cells and nerve regeneration
6. Understanding parallels of human and animal parenting can benefit generations to come
7. Microtubule-based strategies for promoting nerve regeneration after injury
8. Smart Technology Consumers Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet
9. NXT-IDs Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st
10. Researcher using next-generation sequencing to rapidly identify pathogens
11. NRG1 isoforms could be an effective therapeutic candidate to promote peripheral nerve regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blueprint for next generation of chronic myeloid leukemia treatment
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: